Northwest Biotherapeutics, Inc.

NWBO

US66737P6007

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 01:28:43 29/05/2024 am IST			5-day change	1st Jan Change
0.4337 ^USD	-1.43%		-5.41%	-38.13%

10/05	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
21/03	Northwest Biotherapeutics, Inc. Appoints Pat Sarma to Its Board of Directors	CI

Northwest Biotherapeutics: Q1 Earnings Snapshot

May 11, 2023 at 10:55 pm IST

BETHESDA, Md. (AP) — BETHESDA, Md. (AP) — Northwest Biotherapeutics Inc. (NWBO) on Wednesday reported a loss of $10.7 million in its first quarter.

The Bethesda, Maryland-based company said it had a loss of 1 cent per share.

The cancer drug developer posted revenue of $880,000 in the period.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NWBO at https://www.zacks.com/ap/NWBO

For copyright information, check with the distributor of this item, STATS Perform dba Automated Insights. , source Associated Press News

Latest news about Northwest Biotherapeutics, Inc.

Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	11/05	CI
Northwest Biotherapeutics, Inc. Appoints Pat Sarma to Its Board of Directors	21/03	CI
Northwest Biotherapeutics, Inc. Announces Retirement of Jerry Jasinowski from the Board of Directors	15/03	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03	CI
Northwest Biotherapeutics Announces Marketing Authorization Application Has Been Submitted to the UK MHRA for DCVax-L for Glioblastoma	21/12	CI
Northwest Biotherapeutics, Inc. announced that it has received $11.005 million in funding from Streeterville Capital, LLC	10/11	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Northwest Biotherapeutics Appoints Linda Liau to its Scientific Advisory Board	12/23/12	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	01/23/01	CI
Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	28/23/28	CI
Transcript : Northwest Biotherapeutics, Inc. - Shareholder/Analyst Call	31/22/31
Northwest Biotherapeutics Sues Citadel Securities, Other Market Market Makers for Alleged Stock Price Manipulation	01/22/01	MT
Northwest Biotherapeutics Reports Positive Top-Line Results from Phase 3 Trial of DCVax®-L for Glioblastoma	17/22/17	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/22/10	CI
Northwest Biotherapeutics Files $250 Million Mixed Shelf	19/22/19	MT
Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan by MHRA	23/22/23	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	10/22/10	CI
Northwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing At Sawston, Uk Facility	06/22/06	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	10/22/10	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	01/22/01	CI
Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	01/22/01	CI
Northwest Biotherapeutics Announces Commencement of Cancer Vaccine Production At Its Sawston, UK Facility	17/22/17	CI
Northwest Biotherapeutics Announces MHRA Approval Of License for GMP Manufacturing at Sawston, UK Facility	21/21/21	CI

Chart Northwest Biotherapeutics, Inc.

Duration

Period

More charts

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Companyâs wholly owned subsidiaries include Flaskworks, LLC, Northwest Biotherapeutics Limited, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NORTHWEST BIOTHERAPEUTICS, INC.	-38.13%	53Cr
VERTEX PHARMACEUTICALS INCORPORATED	+9.83%	12TCr
REGENERON PHARMACEUTICALS, INC.	+10.80%	11TCr
BIONTECH SE	-10.84%	2.34TCr
ARGENX SE	-1.69%	2.21TCr
GENMAB A/S	-10.23%	1.83TCr
WUXI APPTEC CO., LTD.	-41.92%	1.66TCr
BEIGENE, LTD.	-15.11%	1.6TCr
NEUROCRINE BIOSCIENCES, INC.	+6.62%	1.4TCr
SAREPTA THERAPEUTICS, INC.	+17.53%	1.17TCr